GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ventyx Biosciences Inc (NAS:VTYX) » Definitions » Cash Flow from Investing

VTYX (Ventyx Biosciences) Cash Flow from Investing : $-15.51 Mil (TTM As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Ventyx Biosciences Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Dec. 2024, Ventyx Biosciences spent $0.01 Mil on purchasing property, plant, equipment. It gained $0.00 Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $75.24 Mil on purchasing investments. It gained $64.25 Mil from selling investments. It paid $0.00Mil for net Intangibles purchase and sale. And it paid $0.00 Mil for other investing activities. In all, Ventyx Biosciences spent $11.00 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Dec. 2024.


Ventyx Biosciences Cash Flow from Investing Historical Data

The historical data trend for Ventyx Biosciences's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ventyx Biosciences Cash Flow from Investing Chart

Ventyx Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash Flow from Investing
Get a 7-Day Free Trial - -214.37 -74.93 100.94 -15.51

Ventyx Biosciences Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 46.13 41.77 -75.52 29.25 -11.00

Ventyx Biosciences Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Ventyx Biosciences's Cash Flow from Investing for the fiscal year that ended in Dec. 2024 is calculated as:

Ventyx Biosciences's Cash Flow from Investing for the quarter that ended in Dec. 2024 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-15.51 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ventyx Biosciences  (NAS:VTYX) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Ventyx Biosciences's purchase of property, plant, equipment for the three months ended in Dec. 2024 was $-0.01 Mil. It means Ventyx Biosciences spent $0.01 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Ventyx Biosciences's sale of property, plant, equipment for the three months ended in Dec. 2024 was $0.00 Mil. It means Ventyx Biosciences gained $0.00 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Ventyx Biosciences's purchase of business for the three months ended in Dec. 2024 was $0.00 Mil. It means Ventyx Biosciences spent $0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Ventyx Biosciences's sale of business for the three months ended in Dec. 2024 was $0.00 Mil. It means Ventyx Biosciences gained $0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Ventyx Biosciences's purchase of investment for the three months ended in Dec. 2024 was $-75.24 Mil. It means Ventyx Biosciences spent {stock_data.stock.currency_symbol}}75.24 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Ventyx Biosciences's sale of investment for the three months ended in Dec. 2024 was $64.25 Mil. It means Ventyx Biosciences gained $64.25 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Ventyx Biosciences's net Intangibles purchase and sale for the three months ended in Dec. 2024 was $0.00 Mil. It means Ventyx Biosciences paid $0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Ventyx Biosciences's cash from discontinued investing activities for the three months ended in Dec. 2024 was 0.00 Mil. It means Ventyx Biosciences paid $0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Ventyx Biosciences's cash from other investing activities for the three months ended in Dec. 2024 was $-0.00 Mil. It means Ventyx Biosciences paid $0.00 Mil for other investing activities.


Ventyx Biosciences Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Ventyx Biosciences's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Ventyx Biosciences Business Description

Traded in Other Exchanges
N/A
Address
12790 El Camino Real, Suite 200, San Diego, CA, USA, 92130
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
Executives
John Nuss officer: Chief Scientific Officer C/O VENTYX BIOSCIENCES, INC., 332 ENCINITAS BLVD. SUITE 200, ENCINITAS CA 92024
Sheila Gujrathi director 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121
Raju Mohan director, officer: Chief Executive Officer C/O VENTYX BIOSCINECES, INC., 332 ENCINITAS BLVD., SUITE 200, ENCINITAS CA 92024
Martin Auster officer: Chief Financial Officer C/O VENTYX BIOSCIENCES, INC., 662 ENCINITAS BLVD. STE 250, ENCINITAS CA 92024
Christopher W Krueger officer: Chief Business Officer C/O ARDEA BIOSCIENCES INC, 2131 PALOMAR AIRPORT ROAD SUITE 300, CARLSBAD CA 92011
Nsv Partners Iii Lp 10 percent owner 500 WEST PUTNAM AVE, SUITE 400, GREENWICH CT 06830
Somu Subramaniam director, 10 percent owner C/O ICAD INC, 98 SPIT BROOK ROAD SUITE 100, NASHUA NH 03062
William J. Sandborn officer: See Remarks C/O VENTYX BIOSCIENCES, INC., 662 ENCINITAS BLVD. STE 250, ENCINITAS CA 92024
William Richard White director C/O AKERO THERAPEUTICS, INC., 170 HARBOR WAY 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080
Onaiza Cadoret-manier director 2855 GAZELLE COURT, C/O IONIS PHARMACEUTICALS, INC., CARLSBAD CA 92010
Allison Hulme director C/O SOPHIRIS BIO INC., 1258 PROSPECT ST, LA JOLLA CA 92037
Venbio Global Strategic Fund Iii, L.p. 10 percent owner, other: See Remarks 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Aaron Royston director, 10 percent owner 200 CARDINAL WAY, 2ND FLOOR, REDWOOD CITY CA 94063
Cormorant Asset Management, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Private Healthcare Fund Iii Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116

Ventyx Biosciences Headlines

From GuruFocus